After 20 years of using economic evaluation, should NICE be considered a methods innovator?


13 January 2020 - NICE is only one of several organisations internationally that uses economic evaluation as part of decision making regarding funding and pricing of new medical technologies. 

However, it can be argued that NICE has developed a more prominent international profile than most in their use of economics. After 20 years of operation, it is timely to assess the extent of NICE’s achievements, including the economic evaluation methods it has used and its willingness to adapt these as new evaluative approaches emerge and when NICE faces particular policy challenges. 

This paper considers some of the important policy and contextual developments in the UK over the last 20 years and how these may have shaped NICE’s approach to economic evaluation.

Read PharmacoEconomics article

Michael Wonder

Posted by:

Michael Wonder